Journal Logo

September 2005 - Volume 16 - Issue 8
pp: 797-899

Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats

Abramjuk, Claudia; Jung, Klaus; Krell, Hans-Willi; More

Anti-Cancer Drugs. 16(8):855-861, September 2005.

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC

von Minckwitz, G.; Chernozemsky, I.; Sirakova, L.; More

Anti-Cancer Drugs. 16(8):871-877, September 2005.

Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5–7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy

Markopoulos, C.; Chrissochou, M.; Michailidou, A.; More

Anti-Cancer Drugs. 16(8):879-883, September 2005.